SCHEMBL269805

SCHEMBL269805

CC(O)CN(Cc1cccc(C(=O)Nc2sc3ccccc3c2C(=O)NN=Cc2ccc(F)cc2)c1)CC(C)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGG1 O15527 1/20 0.45
RAB9A P51151 7/20 0.44
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
NPC1 O15118 5/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
MGAM O43451 1/20 0.41
POLB P06746 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
SLC34A2 O95436 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MITF O75030 1/20 0.38
PKM P14618 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269804 1.00 OGG1 (0.45) OGG1RAB9AKMT2AMEN1NPC1
SCHEMBL267500 0.93 XBP1 (0.45) OGG1RAB9AKMT2AMEN1NPC1
SCHEMBL267501 0.93 XBP1 (0.45) OGG1RAB9AKMT2AMEN1NPC1
SCHEMBL268262 0.93 NPC1 (0.42) OGG1RAB9AKMT2AMEN1NPC1
SCHEMBL268263 0.93 NPC1 (0.42) OGG1RAB9AKMT2AMEN1NPC1
SCHEMBL269186 0.91 MAPT (0.43) RAB9AKMT2AMEN1NPC1GAA
SCHEMBL269187 0.91 MAPT (0.43) RAB9AKMT2AMEN1NPC1GAA
SCHEMBL265237 0.90 SLC34A2 (0.39) RAB9AKMT2AMEN1NPC1SMN1; SMN2
SCHEMBL265236 0.90 SLC34A2 (0.39) RAB9AKMT2AMEN1NPC1SMN1; SMN2
SCHEMBL268028 0.88 RAB9A (0.47) RAB9AKMT2AMEN1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 OGG1 4720/4885RAB9A 883/4885KMT2A 4564/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 OGG1 4677/4885RAB9A 1362/4885KMT2A 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.